Johannes Landskron

Johannes Landskron is a Researcher at the Norwegian Centre for Molecular Biosciences and Medicine (NCMBM), University of Oslo, where he has served as Head of the High-Throughput Chemical Biology Screening Platform since 2017. His work bridges molecular immunology, cancer biology, and drug discovery, with a focus on regulatory T cells, signaling pathways, and high-throughput screening technologies.

Education:

• PhD (Dr. rer. nat.), Institute of Zoology, University of Regensburg, Germany (2007)

Research Interests:
Johannes Landskron specializes in cell signaling, particularly in immune cells, and employs high-throughput screening and flow cytometry to explore mechanisms in cancer immunology and circadian biology. His work on regulatory T cells, FoxP3 regulation, and ovarian cancer microenvironment has led to impactful publications. He also investigates marine fungi-derived compounds for anticancer potential.

Publication Trends:
His recent publications (2023–2025) emphasize immunomodulatory drug discovery, circadian clock mechanisms in Drosophila, and the impact of tumor microenvironment on drug response. The recurring themes include T-cell regulation, signaling pathway analysis, and phenotypic screening, demonstrating a strong interdisciplinary approach integrating molecular biology, genomics, and chemical biology.

Scientific Awards:

• No awards explicitly mentioned in the provided text.

Advising and Grants:
While no formal students are listed, Landskron has led significant research projects funded by the K.G. Jebsen Centre for Cancer Immunotherapy and the FUGE program. He has also contributed to EU-OPENSCREEN, a major collaborative chemical biology initiative, highlighting his role in large-scale, funded research infrastructure.

Labs and Teams:
Landskron leads the High-Throughput Chemical Biology Screening Platform at NCMBM. He has been a key member of the Taskén Group, focusing on cancer immunology and signal transduction. His collaborative work spans multiple institutions and consortia, particularly in EU-OPENSCREEN and studies involving patient-derived cancer models.